Johnson & Johnson Share Price Mexican S.E.

Equities

JNJ *

US4781601046

Pharmaceuticals

End-of-day quote Mexican S.E. 03:30:00 14/05/2024 am IST 5-day change 1st Jan Change
2,549 MXN -1.73% Intraday chart for Johnson & Johnson +1.31% -3.66%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 8.84TCr 1,48300Cr 7,37500Cr Sales 2025 * 9.08TCr 1,52400Cr 7,57600Cr Capitalization 36TCr 6,11400Cr 30,40300Cr
Net income 2024 * 2.2TCr 37TCr 1,83900Cr Net income 2025 * 2.31TCr 39TCr 1,92700Cr EV / Sales 2024 * 4.04 x
Net cash position 2024 * 699.71Cr 12TCr 58TCr Net cash position 2025 * 2.11TCr 35TCr 1,75900Cr EV / Sales 2025 * 3.78 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
15.9 x
Employees 1,31,900
Yield 2024 *
3.19%
Yield 2025 *
3.33%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.73%
1 week+1.31%
Current month+2.58%
1 month+3.87%
3 months-3.99%
6 months-0.51%
Current year-3.66%
More quotes
1 week
2 501.01
Extreme 2501.01
2 593.99
1 month
2 443.01
Extreme 2443.01
2 593.99
Current year
2 443.01
Extreme 2443.01
2 794.00
1 year
2 443.01
Extreme 2443.01
3 000.00
3 years
2 443.01
Extreme 2443.01
3 799.98
5 years
2 440.00
Extreme 2440
3 891.00
10 years
1 259.80
Extreme 1259.8
3 891.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 01/89/01
Director of Finance/CFO 57 01/98/01
Chief Tech/Sci/R&D Officer 58 05/19/05
Members of the board TitleAgeSince
Director/Board Member 70 25/19/25
Director/Board Member 72 19/14/19
Director/Board Member 70 22/09/22
More insiders
Date Price Change Volume
14/24/14 2,549 -1.73% 2,988
13/24/13 2,594 +3.06% 6,155
10/24/10 2,517 -0.00% 149
09/24/09 2,517 +0.04% 75
07/24/07 2,516 +0.32% 613

End-of-day quote Mexican S.E., May 14, 2024

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.4 USD
Average target price
173.3 USD
Spread / Average Target
+14.46%
Consensus
1st Jan change Capi.
+31.49% 59TCr
+19.26% 33TCr
+5.20% 29TCr
+15.36% 24TCr
+9.99% 21TCr
-6.91% 20TCr
+9.97% 17TCr
-0.50% 16TCr
+1.24% 12TCr
Other Pharmaceuticals
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW